What is Incyte's SG&A?

Incyte (INCY) reported SG&A of $351.74M in Q2 2026.

How has Incyte's SG&A changed year-over-year?

Incyte's SG&A increased by 6.3% year-over-year, from $331.02M to $351.74M.

What is the long-term trend for Incyte's SG&A?

Over 4 years (2021 to 2025), Incyte's SG&A has grown at a 16.8% compound annual growth rate (CAGR), from $739.56M to $1.38B.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Incyte INCY SG&A

SG&A at other companies

Bristol-Myers SquibbBMY

$1.83B+6.6%

PfizerPFE

$2.96B-2.3%

Gilead SciencesGILD

$1.45B+15.3%

GeronGERN

$35.43M-11.5%

Syndax PharmaceuticalsSNDX

$44.92M+48.6%

Agios PharmaceuticalsAGIO

$51.55M+12.4%

Other financials

Income statement

See full

Revenue$1.7B+37.7%

Gross profit$1.6B+38.0%

Operating income$697.9M+31.6%

Net income$585.6M+44.6%

EPS (diluted)$2.81+37.7%

Balance sheet

See full

Cash & equivalents$4.0B+104%

Total debt$38.3M-9.8%

Total equity$6.3B+52.1%

Total assets$7.9B+35.2%

Cash flow

See full

Operating cash flow$507.7M+1,035%

CapEx$1.6M-43.5%

Free cash flow$509.3M+1,069%

Valuation

See full

Market cap$25.96B+70.1%

Enterprise value$22.01B+64.9%

P/E16.1×-1.4×

P/S4.5×+1.1×

Profitability

See full

Gross margin92.6%-0.3pp

Operating margin30.6%+4.8pp

Net margin27.7%+8.7pp

FCF margin34%+12.3pp

Returns & leverage

See full

Return on equity30.7%+6.4pp

Debt / equity0×0.0×

Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Incyte's SG&A?: Incyte (INCY) reported SG&A of $351.74M in Q2 2026.
How has Incyte's SG&A changed year-over-year?: Incyte's SG&A increased by 6.3% year-over-year, from $331.02M to $351.74M.
What is the long-term trend for Incyte's SG&A?: Over 4 years (2021 to 2025), Incyte's SG&A has grown at a 16.8% compound annual growth rate (CAGR), from $739.56M to $1.38B.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.